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Cardiac magnetic resonance imaging (CMR) has long
been recognized as an accurate and reliable means of
evaluating cardiac anatomy and ventricular function.
Considerable progress has been made in the field of
CMR, providing accurate evaluation of myocardial
ischemia and infarction [1, 2]. Contrast-enhanced
CMR can be used to visualize the transmural extent
of myocardial infarction with high spatial resolution
[3–5]. Infarcted myocardium appears hyperenhanced
compared with normal myocardium when imaged by
a delayed-enhancement MRI technique with the use
of T1-weighted sequence after injection of gadolin-
ium chelates. Late gadolinium-enhanced CMR can
clearly delineate subendocardial infarction and the
transmural extent of delayed enhancement potentially
predicts functional outcome after revascularization in
acute myocardial infarction and chronic ischemic
heart disease. This indicates that the late enhance-
ment technique can accurately discriminate between
infarction and dysfunctional but viable myocardium.
Experimental and clinical studies have shown that the
extent of delayed enhancement is reproducible and
closely correlates with the size of myocardial necro-
sis or infarct scar as determined by established in
vitro and in vivo methods. Furthermore, CMR
appears to be more sensitive than other imaging
methods in detecting small subendocardial
infarctions.
Stress first-pass contrast-enhanced myocardial per-
fusion CMR can be used to detect subendocardial
ischemia [6, 7], and recent studies have demonstrated
the high diagnostic accuracy of stress myocardial
perfusion CMR for detecting significant coronary
artery disease. Free-breathing, whole-heart coronary
angiography (MRA) was recently introduced as a
method that can provide visualization of all three
major coronary arteries and coronary bypasses within
a single three-dimensional acquisition [8]. With
further improvements in CMR techniques and the
establishment of a standardized study protocol, CMR
will play a pivotal role in imaging patients with
ischemic heart disease.
In recent years, late gadolinium enhancement CMR
has also been used to visualize myocardial interstitial
abnormalities. Studies by the groups of Pennell et al.
and Sechtem et al. [9–12] have clearly shown late
enhancement patterns in patients with different forms
of cardiomyopathies, amyloidosis, myocarditis, stor-
age diseases etc. Silva et al. [10] showed that late
enhancement can be demonstrated in cardiomyopathy
patients, with a mean signal intensity of 390 ± 220%
compared with normal regions. The distribution
pattern of late enhancement was unlike the subendo-
cardial late enhancement related to coronary territories
found in myocardial infarction. The affected areas
included papillary muscles (sarcoid), the mid-myocar-
dium (Anderson–Fabry disease, glycogen storage
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disease, myocarditis, Becker muscular dystrophy) and
the global subendocardium (systemic sclerosis, Loef-
fler’s endocarditis, amyloid, Churg-Strauss). Focal
myocardial late gadolinium enhancement is found in
the specific cardiomyopathies, and the pattern is
distinct from that seen in myocardial infarction.
Vogelsberg et al. [12] showed in patients with
biopsy-proven cardiac amyloidosis, that late gadolin-
ium enhancement frequently occurs in a peculiar
pattern. Consequently, noninvasive CMR can be used
to diagnose or rule out cardiac amyloidosis with good
sensitivity and excellent specificity in a clinical routine
setting. In a recent study Hartke et al. [13] demon-
strated right ventricular late gadolinium enhancement
in patients with congenital heart disease and right
ventricular loading conditions. Clinical variables were
associated with the presence of fibrosis but did not
reliably predict severity. Myocardial preservation is
likely a multifactorial process that may affect the right
and left ventricles differently [14].
In an article in the present issue, Bohl et al. [15]
aim to systematically categorize late enhancement
patterns in a variety of non-ischemic heart diseases
and to explore their relationship with left ventricular
function. The authors evaluated 156 patients with
NIHD who exhibited late enhancement on CMR.
Late enhancement was correlated to left ventricular
function. It was clearly shown that late enhancement
spared the subendocardium. Consistent late enhance-
ment patterns were observed in myocarditis,
hypertrophic and dilated cardiomyopathy and sys-
temic vasculitis. No conclusive late enhancement
patterns were observed in patients with aortic steno-
sis, arterial hypertension, lupus erythematosus,
sarcoidosis, ventricular arrhythmia and in a mixed
subgroup of rare non-ischemic heart diseases. There
was no significant relationship between late enhance-
ment and ejection fraction. There was no correlation
between end diastolic volume and late enhancement
in either myocarditis or dilated cardiomyopathy. Late
enhancement was unrelated to left ventricular mass in
aortic stenosis and hypertrophic cardiomyopathy.
This interesting study therefore proposed a meth-
odological approach with which to describe and
categorize late enhancement in patients with non-
ischemic heart diseases. Distinct late enhancement
patterns were demonstrated in four of the investigated
subgroups with non-ischemic heart disease i.e. myo-
carditic type, dilated cardiomyopathy type,
hypertrophic cardiomyopathy type and vasculitic
type. A number of rare late enhancement phenotypes
were elucidated that had not been described yet.
Finally, it was shown that the extent of tissue injury
in non-ischemic heart disease is, unlike in coronary
artery disease, largely independent of systolic left
ventricular function. Unlike in ischemic heart dis-
ease, the structure–function relationship did not
appear to be strong. As the authors correctly state, a
variety of myocardial tissue alterations occur, all of
which may provide candidate substrates for positive
late enhancement. Although late enhancement studies
in non-ischemic heart disease are very encouraging,
more sophisticated CMR techniques and prognostic
clinical studies are warranted to understand the true
underlying mechanisms and consequences of late
myocardial contrast enhancement.
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